
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Dement Neuropsychol</journal-id><journal-id journal-id-type="iso-abbrev">Dement Neuropsychol</journal-id><journal-id journal-id-type="publisher-id">dn</journal-id><journal-title-group><journal-title>Dementia &#x00026; Neuropsychologia</journal-title></journal-title-group><issn pub-type="ppub">1980-5764</issn><publisher><publisher-name>Associa&#x000e7;&#x000e3;o de Neurologia Cognitiva e do
Comportamento</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29213377</article-id><article-id pub-id-type="pmc">5619558</article-id><article-id pub-id-type="doi">10.1590/s1980-57642008dn10200002</article-id><article-categories><subj-group subj-group-type="heading"><subject>Views &#x00026; Reviews</subject></subj-group></article-categories><title-group><article-title>Targeting the gastrin-releasing peptide receptor pathway to treat
cognitive dysfunctionassociated with Alzheimer&#x02019;s Disease</article-title><trans-title-group xml:lang="pt"><trans-title>O receptor do pept&#x000ed;deo liberador de gastrina como novo alvo
terap&#x000ea;utico para o tratamento da disfun&#x000e7;&#x000e3;o cognitiva
associada &#x000e0; Doen&#x000e7;a de Alzheimer</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Roesler</surname><given-names>Rafael</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="c1"/></contrib><contrib contrib-type="author"><name><surname>Luft</surname><given-names>Tatiana</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Schwartsmann</surname><given-names>Gilberto</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Cellular and Molecular Neuropharmacology Research Group,
Department of Pharmacology, Institute for Basic Health Sciences, Federal University
of Rio Grande do Sul, 90046-900 Porto Alegre, RS, Brazil.</aff><aff id="aff2"><label>2</label>Cancer Research Laboratory, Academic Hospital Research
Center, Federal University of Rio Grande do Sul, 90035-003 Porto Alegre, RS,
Brazil.</aff><aff id="aff3"><label>3</label>Department of Biochemistry, Institute for Basic Health
Sciences, Federal University of Rio Grande do Sul, 90035-003 Porto Alegre, RS,
Brazil.</aff><aff id="aff4"><label>4</label>Department of Internal Medicine, Faculty of Medicine,
Federal University of Rio Grande do Sul, 90035-003 Porto Alegre, RS, Brazil</aff><author-notes><corresp id="c1"><bold>Dr. Rafael Roesler</bold> &#x02013; Department Neuropharmacology,
Institute for Basic Health Sciences, Federal University of Rio Grande do Sul.
Rua Sarmento Leite 500 - 90046-900 Porto Alegre RS - Brazil. E-mail:
<email>rroesler@terra.com.br</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Apr-Jun</season><year>2007</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Apr-Jun</season><year>2007</year></pub-date><volume>1</volume><issue>2</issue><fpage>118</fpage><lpage>123</lpage><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><p>Increasing evidence indicates that bombesin (BB)-like peptides (BLPs), such as
the gastrin-releasing peptide (GRP) and its receptor (GRPR), might play a role
in neurological and psychiatric disorders. The present study reviews findings
from animal and human studies suggesting that the GRPR should be considered a
target for the treatment of cognitive dysfunction in patients with Alzheimer&#x02019;s
disease (AD). Abnormalities in GRPR-triggered signaling have been described in
both fibroblasts from patients with AD, and in transgenic mouse models of AD.
Pharmacological and genetic preclinical studies have indicated that BLPs and the
GRPR are importantly involved in regulating cognitive function. Moreover, drugs
acting at the GRPR have been shown to enhance memory and ameliorate cognitive
dysfunction in experimental models of amnesia associated with AD. Taken
together, these findings support the view that the GRPR is a novel therapeutic
target for the treatment of memory deficits associated with AD.</p></abstract><trans-abstract xml:lang="pt"><p>Estudos recentes indicam que os pept&#x000ed;deos da fam&#x000ed;lia da bombesina
(BB), como o pept&#x000ed;deo liberador de gastrina (GRP) e seu receptor (GRPR),
podem estar envolvidos em doen&#x000e7;as neurol&#x000f3;gicas e
psiqui&#x000e1;tricas. Este artigo apresenta uma revis&#x000e3;o de estudos tanto
em humanos como em modelos animais que sugerem que o GRPR deve ser considerado
um alvo molecular para o desenvolvimento de novas terapias para o tratamento de
d&#x000e9;ficits cognitivos em pacientes com doen&#x000e7;a de Alzheimer (DA).
Anormalidades na sinaliza&#x000e7;&#x000e3;o celular dependente do GRPR t&#x000ea;m
sido descritas tanto em fibroblastos de pacientes com DA como em modelos de DA
em camundongos transg&#x000ea;nicos. Al&#x000e9;m disso, estudos
pr&#x000e9;-cl&#x000ed;nicos utilizando estrat&#x000e9;gias farmacol&#x000f3;gicas e
gen&#x000e9;ticas indicam que os pept&#x000ed;deos da fam&#x000ed;lia da BB e o
GRPR est&#x000e3;o envolvidos de forma importante na regula&#x000e7;&#x000e3;o da
fun&#x000e7;&#x000e3;o cognitiva. Finalmente, resultados recentes mostram que
drogas que agem como ligantes do GRPR podem melhorar a mem&#x000f3;ria e prevenir
disfun&#x000e7;&#x000f5;es cognitivas em modelos experimentais de amn&#x000e9;sia
asssociada &#x000e0; DA. Em conjunto, os dados indicam que o GRPR &#x000e9; um
novo alvo terap&#x000ea;utico para o tratamento de d&#x000e9;ficits de
mem&#x000f3;ria associadas &#x000e0; DA.</p></trans-abstract><kwd-group><kwd>bombesin-like peptides</kwd><kwd>gastrin-releasing peptide</kwd><kwd>gastrin-releasing peptide receptor</kwd><kwd>cognitive enhancers</kwd><kwd>memory disorders</kwd><kwd>Alzheimer disease</kwd></kwd-group></article-meta></front><body><sec><title>Bombesin-like peptides and their receptors in the brain</title><p>Bombesin (BB) is a 14 amino acid initially isolated from the skin of frogs
<italic>Bombina bombina</italic>. It was later described that gastrin-releasing
peptide (GRP), a 27 amino acid peptide functionally and structurally related to BB,
is a mammalian counterpart of BB (<xref ref-type="table" rid="t1">Table 1</xref>).
BB and GRP, as well as other related peptides such as neuromedin (NM) B (NMB),
constitute a family of BB-like peptides (BLPs). BLPs have been described to affect a
range of cellular and neuroendocrine functions, including cell proliferation and
differentiation, cancer growth, feeding behavior, and stress responses (for recent
reviews, see<sup><xref rid="r1" ref-type="bibr">1</xref>-<xref rid="r4" ref-type="bibr">4</xref></sup>) .</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Structures of bombesin (BB) and gastrin-releasing peptide (GRP).</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="100%" span="1"/></colgroup><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Bombesin</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Pyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Gastrin-releasing peptide</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Ala-Pro-Val-Ser-Val-Gly-Gly-Gly-Thr-Val-Leu-Ala-Lys-Met-Tyr-Pro-Arg-Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>Adapted from <sup>[<xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r7" ref-type="bibr">7</xref>]</sup>.</p></fn></table-wrap-foot></table-wrap><p>Early studies investigating the presence of BB binding sites in the mammalian central
nervous system (CNS) showed that BB bound with high affinity to rat brain membranes.
The hippocampus, a brain area critically involved in cognitive function and
neurodegenerative and neuropsychiatric disorders, including Alzheimer&#x02019;s disease
(AD), had the highest density of specific BB binding sites.<sup><xref rid="r5" ref-type="bibr">5</xref></sup> Subsequent studies identified the
occurrence of endogenous BLPs as neuropeptides in the rat CNS. It is now well
established that GRP, the main mammalian BLP, is like a co-transmitter released from
both central and peripheral neurons that regulates aspects of brain function
including memory and emotional processing (for reviews, see<sup><xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r4" ref-type="bibr">4</xref></sup>) (<xref ref-type="table" rid="t1">Table 1</xref>).</p></sec><sec><title>The gastrin-releasing peptide (GRPR) receptor and associated signal transduction
pathways</title><p>BB and GRP exert most of their biological actions by binding at the GRP receptor
(GRPR, also known as BB2 receptor). GRPR is a member of the G-protein coupled
receptor superfamily containing seven transmembrane domains and 384 amino
acids.<sup><xref rid="r6" ref-type="bibr">6</xref>-<xref rid="r8" ref-type="bibr">8</xref></sup> GRPR is highly expressed in the brain. Studies using
in vitro autoradiographic techniques have indicated that brain areas containing high
densities of GRPRs include the olfactory bulb, nucleus accumbens, caudate putamen,
central amygdala, dorsal hippocampal formation, as well as the paraventricular,
central medial, and paracentral thalamic nuclei.<sup><xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref></sup> A recent
seminal immunohistochemical study has used affinity-purified GRPR antibodies to
examine the precise distribution of GRPR in the mouse brain. GRPR immunoreactivity
was widely distributed in the isocortex, hippocampus, piriform cortex, amygdala,
hypothalamus, and brain stem, with high concentrations in the dorsal hippocampus and
lateral amygdala. In addition, GRPR expression was specific for the cell membranes
of neuronal dendrites and cell bodies.<sup><xref rid="r11" ref-type="bibr">11</xref></sup></p><p>Intracellular responses to GRPR activation were initially examined in cancer and
neuroendocrine cell lines. Cellular signaling pathways for the GRPR have been shown
to include protein kinase signaling cascades, particularly the protein kinase C
(PKC) and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated
protein kinase (ERK) pathways.<sup><xref rid="r12" ref-type="bibr">12</xref>-<xref rid="r14" ref-type="bibr">14</xref></sup> In the brain, GRP-induced neuronal
membrane depolarization in the rat hippocampus is blocked by a PLC
inhibitor,<sup><xref rid="r15" ref-type="bibr">15</xref></sup> and we have
recently shown that modulation of the rat hippocampal function by BB depends on the
PKC, MAPK and PKA pathways (<xref ref-type="fig" rid="f1">Figure</xref>).<sup><xref rid="r16" ref-type="bibr">16</xref></sup></p><p><fig id="f1" orientation="portrait" position="float"><label>Figure</label><caption><p>Proposed signaling pathways associated with the gastrinreleasing peptide
receptor (GRPR) in the central nervous system. Gastrin-releasing peptide
(GRP) released from synaptic terminals binds to the G<sub>q</sub>
protein-coupled GRPR at postsynaptic sites. GRPR activation induces an
increase in [Ca<sup>2+</sup>] and triggers activation of
the phospholipase C (PLC)/protein kinase C (PKC) pathway, which, in
turn, can activate mitogen-activated protein kinase (MAPK). The dopamine
D1/D5 receptor (D1R) is coupled to Gs protein (G<sub>s</sub>) and
adenylyl cyclase (AC) activation. The D1R-induced cAMP signal might be
synergistically potentiated by [Ca<sup>2+</sup>]-induced
stimulation of [Ca<sup>2+</sup>]-responsive types of AC,
leading to increased activation of protein kinase A (PKA). Reproduced
from [16], with permission.</p></caption><graphic xlink:href="dn-01-02-0118-g01"/></fig></p><p>An increasing body of evidence indicates that BLPs and the GRPR might play a role in
CNS disease, including memory disorders associated with AD and other
neurodegenerative disorders. Thus, our group has put forward the GRPR as a novel
therapeutic target for the development of therapies to treat neurological and
psychiatric disorders.<sup><xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r17" ref-type="bibr">17</xref></sup> The present study reviews current
evidence suggesting the GRPR should be considered a target for the treatment of
cognitive dysfunction in patients with AD.</p></sec><sec><title>Abnormalities in GRPR function in Alzheimer&#x02019;s disease: evidence from mice and
human studies</title><p>Increasing evidence from animal and human studies has indicated that abnormalities in
BLPs- and GRPR-triggered cellular signaling might be associated with AD.
Dysregulation of calcium signaling has been causally implicated in both normal brain
aging and AD. BB stimulates calcium release from BB-releasable calcium stores in the
endoplasmic reticulum (ER). Exaggerated BB-induced intracellular calcium release has
been demonstrated in fibroblasts and neurons from genetically modified mice bearing
a mutation in the presenilin-1 (PS-1) mutation.<sup><xref rid="r18" ref-type="bibr">18</xref></sup> These transgenic mice have been developed as a useful
animal model since mutations in the presenilin-1 (PS1) gene on chromosome 14 are
causally linked to many cases of early-onset inherited AD.<sup><xref rid="r18" ref-type="bibr">18</xref>,<xref rid="r19" ref-type="bibr">19</xref></sup>
Importantly, the alterations in BB-induced enhancement of calcium signaling observed
in this mouse model resemble those described in patients with AD. Both increased and
reduced calcium signals have been described in AD patients. Thus, fibroblasts from
familial and non-familial AD cases have shown enhanced calcium signals induced by BB
compared to controls.<sup><xref rid="r20" ref-type="bibr">20</xref>-<xref rid="r24" ref-type="bibr">24</xref></sup> In contrast, in fibroblasts from
patients with familial Alzheimer&#x02019;s disease presenting the Swedish APP670/671
mutation, BB-induced elevations in calcium were found to be reduced by
40%.<sup><xref rid="r21" ref-type="bibr">21</xref></sup> These abnormalities
in BB-regulated calcium homeostasis observed in AD fibroblasts have been proposed to
involve alterations in oxidative stress.<sup><xref rid="r20" ref-type="bibr">20</xref>-<xref rid="r23" ref-type="bibr">23</xref>,<xref rid="r25" ref-type="bibr">25</xref></sup> Since alterations in calcium signaling and
oxidative stress might be involved in neurodegeneration and cognitive impairment in
AD patients, these findings from mouse and human studies support the view that
BLP-triggered signaling and the GRPR pathway might play a role in the pathogenesis
of AD.</p><p>Another cellular change related to BLP- and GRPR-elicited signaling described in
fibroblasts from patients with AD, is a reduced number of BB receptors.<sup><xref rid="r24" ref-type="bibr">24</xref></sup> This interesting finding raises
the possibility that decreased neuronal GRPR density, leading to impaired BLP
function in the brain of AD patients, is related to neurodegeneration and memory
loss associated with the disease. <xref ref-type="table" rid="t2">Table 2</xref>
summarizes relevant alterations in the GRPR pathway observed in patients with AD
(<xref ref-type="table" rid="t2">Table 2</xref>).</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Abnormalities in the gastrin-releasing peptide receptor (GRPR) pathway in
patients with Alzheimer's disease (AD).</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="90%" span="1"/><col width="10%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Finding</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Enhanced bombesin (BB)-induced calcium release in fi
brobasts</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="r23" ref-type="bibr">23</xref>, <xref rid="r24" ref-type="bibr">24</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Reduced BB-induced calcium mobilization in fibrobasts
in patients with the Swedish APP670/671 mutation</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Increased response of BB-induced calcium release to
oxidant agents in patients with presenilin-1 (PS-1) mutation</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Reduced number of gastrin-releasing peptide receptors
(GRPRs) in fi broblasts</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup></td></tr></tbody></table></table-wrap></sec><sec><title>Effects of drugs acting at the GRPR on cognitive function: preclinical
findings</title><p>The present and other authors have used rodent models of learning and memory to
investigate the role of brain BLPs and the effects of drugs acting at the GRPR in
cognitive function. Systemic administration of BB or GRP enhances memory retention
in rats and mice,<sup><xref rid="r26" ref-type="bibr">26</xref>,<xref rid="r27" ref-type="bibr">27</xref></sup> whereas injections of GRPR
antagonists cause impairment.<sup><xref rid="r28" ref-type="bibr">28</xref>-<xref rid="r32" ref-type="bibr">32</xref></sup> GRPR agonists and antagonists also
modulate memory formation and extinction when infused intracranially into specific
brain areas.<sup><xref rid="r16" ref-type="bibr">16</xref>,<xref rid="r31" ref-type="bibr">31</xref>,<xref rid="r33" ref-type="bibr">33</xref>-<xref rid="r38" ref-type="bibr">38</xref></sup> For instance, GRPR inactivation in
either the dorsal hippocampus or basolateral amygdala by infusions of the selective
GRPR antagonist [D-Tpi,<sup><xref rid="r6" ref-type="bibr">6</xref></sup>
Leu<sup><xref rid="r13" ref-type="bibr">13</xref></sup>
psi(CH<sub>2</sub>NH)-Leu<sup><xref rid="r14" ref-type="bibr">14</xref></sup>] bombesin (6-14) (RC-3095), a synthetic BB analog,
hinders retention of memory for inhibitory avoidance, a type of fear
conditioning-based task, in rats.<sup><xref rid="r31" ref-type="bibr">31</xref>,<xref rid="r36" ref-type="bibr">36</xref>,<xref rid="r37" ref-type="bibr">37</xref></sup> Moreover, the findings from pharmacological
studies are supported by genetic evidence showing altered memory formation and
synaptic plasticity in GRPR-deficient knockout mice.<sup><xref rid="r39" ref-type="bibr">39</xref></sup></p><p>Our group has shown that the dorsal hippocampus is a brain area crucially involved in
mediating the regulatory actions of BLPs on memory.<sup><xref rid="r16" ref-type="bibr">16</xref>,<xref rid="r33" ref-type="bibr">33</xref>,<xref rid="r34" ref-type="bibr">34</xref>,<xref rid="r36" ref-type="bibr">36</xref>,<xref rid="r37" ref-type="bibr">37</xref></sup> Importantly,
microinfusion of BB into the rat CA1 hippocampal area has enhanced inhibitory
avoidance consolidation. We went on to investigate the molecular mechanisms
mediating the memory-enhancing effect of intrahippocampal BB administration.
BB-induced modulation of memory consolidation was prevented by infusion of a GRPR
antagonist or inhibitors of the PKC, MAPK, and PKA signaling pathways. These
findings indicated that BB (and presumably other BLPs) might facilitate cognitive
function by activating GRPRs in hippocampal neuronal membranes, thus leading to
activation of intracellular signal transduction pathways known to mediate synaptic
plasticity and memory formation.<sup><xref rid="r16" ref-type="bibr">16</xref></sup>
Other experiments have suggested that the GRPR signaling system might have
functional interactions with glucocorticoid receptors<sup><xref rid="r37" ref-type="bibr">37</xref></sup> and inhibitory neurons releasing
gamma-aminobutyric acid (GABA)<sup><xref rid="r33" ref-type="bibr">33</xref></sup>
in regulating memory formation in the hippocampus.</p></sec><sec><title>Prevention of memory impairment induced by the Alzheimer peptide through a GRPR
agonist in a rat model</title><p>Our findings described above, that BB can stimulate cellular signaling mechanisms
that mediate synaptic plasticity and enhance memory formation, suggest that BLPs
should be further evaluated as potential cognitive enhancers in experimental
amnesia. In fact, systemic injection of GRP has been shown to attenuate memory
deficits in the scopolamine- and hypoxia-induced models of memory impairment in
mice.<sup><xref rid="r40" ref-type="bibr">40</xref></sup> We thus decided to
examine the effects of GRPR activation by BLPs in an experimental model of memory
disorders associated with AD. Rats were given an infusion of a low dose of the
neurotoxic fragment of beta-amyloid peptide (Abeta 25-35) into the CA1 hippocampal
area. Intrahippocampal administration of Abeta (25-35) produced an impairment of
retention of memory for inhibitory avoidance conditioning. GRPR activation by
administration of BB to the hippocampus before avoidance training prevented the
Abeta (25-35)-induced memory impairment.<sup><xref rid="r16" ref-type="bibr">16</xref></sup> This finding indicates that BB and other GRPR agonists
might prevent cognitive deficits associated with AD. <xref ref-type="table" rid="t3">Table 3</xref> summarizes findings from animal studies supporting the view that
drugs acting on the GRPR might display cognitive-enhancing properties.</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Findings from preclinical studies indicating that drugs acting at the
gastrin-releasing peptide receptor (GRPR) can display cognitive-enhancing
properties.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="80%" span="1"/><col width="10%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Species</th><th align="left" rowspan="1" colspan="1">Finding</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Rat</td><td align="left" rowspan="1" colspan="1">Memory enhancement by systemic administration of
bombesin (BB) or gastrin-releasing peptide (GRP)</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="r26" ref-type="bibr">26</xref>, <xref rid="r27" ref-type="bibr">27</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Rat</td><td align="left" rowspan="1" colspan="1">Enhancement of fear memory by intrahippocampal infusion
of BB</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Rat</td><td align="left" rowspan="1" colspan="1">Memory enhancement by infusion of BB into the nucleus
tractus solitarius (NTS)</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="r38" ref-type="bibr">38</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Rat</td><td align="left" rowspan="1" colspan="1">Enhancement of fear memory by intrahippocampal infusion
of an administration of a GRP receptor (GRPR) antagonist</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="r33" ref-type="bibr">33</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Rat</td><td align="left" rowspan="1" colspan="1">Enhancement of fear memory by intraamygdala infusion of
a GRPR antagonist</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="r35" ref-type="bibr">35</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Mouse</td><td align="left" rowspan="1" colspan="1">Enhancement of fear memory and synaptic plasticity in
GRPR-deficient knockout mice</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="r39" ref-type="bibr">39</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Mouse</td><td align="left" rowspan="1" colspan="1">Improvement of scopolamine and hypoxia-induced amnesia
by systemic administration of GRP</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="r40" ref-type="bibr">40</xref>]</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Rat</td><td align="left" rowspan="1" colspan="1">Prevention of memory impairment induced by beta-amyloid
peptide (25-35) by intrahippocampal infu-sion of BB</td><td align="center" rowspan="1" colspan="1"><sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup></td></tr></tbody></table></table-wrap></sec><sec><title>Perspectives on the clinical use of drugs acting at the GRPR as cognitive
enhancers in patients with Alzheimer&#x02019;s disease</title><p>The data reviewed above can be summarized as follows:</p><p><list list-type="simple"><list-item><p>(1) the human BLP, GRP, and its receptor, GRPR, are expressed in neurons,
and particularly high densities of GRP and GRPR occur in brain areas
importantly involved in cognitive function and dementia, such as the
hippocampus;</p></list-item><list-item><p>(2) evidence from mouse and human studies suggest that abnormalities in
GRPR expression and aspects of GRPR signaling relevant for
neurodegeneration and cognitive function (i.e., cellular calcium
homeostasis, oxidative stress) might be associated with AD;</p></list-item><list-item><p>(3) preclinical studies show that GRP and the GRPR are importantly
involved in regulating synaptic plasticity and memory formation in the
hippocampus and other brain areas; and</p></list-item><list-item><p>(4) GRPR agonists can prevent memory disorders in a rat model of amnesia
associated with AD.</p></list-item></list></p><p>Together, these findings constitute a consistent body of evidence supporting the view
that drugs acting at the GRPR should be further evaluated as potential cognitive
enhancers to treat memory disorders associated with AD and other neurodegenerative
and psychiatric disorders. In addition to the amphibian and mammalian BLPs that act
as GRPR agonists, namely BB and GRP, we have recently shown that the BB analog and
GRPR antagonist RC-3095 can also enhance memory when given at high doses to
rats.<sup><xref rid="r33" ref-type="bibr">33</xref></sup> Thus, both
naturally-occurring BLPs and synthetic BB analogs, might display cognitive-enhancing
properties and could be considered candidate drugs for the treatment of memory
disorders. In addition, our recent findings that the GRPR modulates inflammatory
responses,<sup><xref rid="r41" ref-type="bibr">41</xref></sup> raises the
possibility that GRPR ligands could display neuroprotective actions in addition to
facilitating memory in AD patients. Since previous clinical studies in the fields of
gastroenterology and oncology have indicated that BLPs and RC-3095 do not induce
overt side effects when administered intravenously in humans,<sup><xref rid="r42" ref-type="bibr">42</xref>,<xref rid="r43" ref-type="bibr">43</xref></sup> clinical trials evaluating the effects of drugs acting at
the GRPR on cognitive function in patients with AD and other neurodegenerative and
psychiatric disorders are warranted.</p></sec></body><back><ack><title>Acknowledgements</title><p>Research described in references<sup><xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r16" ref-type="bibr">16</xref>-<xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r28" ref-type="bibr">28</xref>-<xref rid="r31" ref-type="bibr">31</xref>,<xref rid="r33" ref-type="bibr">33</xref>,<xref rid="r34" ref-type="bibr">34</xref>,<xref rid="r36" ref-type="bibr">36</xref>-<xref rid="r37" ref-type="bibr">37</xref>,<xref rid="r41" ref-type="bibr">41</xref>,<xref rid="r43" ref-type="bibr">43</xref></sup> and
reviewed in the present article has been supported by grants from CNPq-Conselho
Nacional de Desenvolvimento Cient&#x000ed;fico e Tecnol&#x000f3;gico and the South
American Office for Anticancer Drug Development, and Zentaris GmbH (Frankfurt,
Germany).</p></ack><ref-list><title>References</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moody</surname><given-names>TW</given-names></name><name><surname>Merali</surname><given-names>Z</given-names></name></person-group><article-title>Bombesin-like peptides and associated receptors within the brain:
distribution and behavioral implications</article-title><source>Peptides</source><year>2004</year><volume>25</volume><fpage>511</fpage><lpage>520</lpage><pub-id pub-id-type="pmid">15134870</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohki-Hamazaki</surname><given-names>H</given-names></name><name><surname>Iwabuchi</surname><given-names>M</given-names></name><name><surname>Maekawa</surname><given-names>F</given-names></name></person-group><article-title>Development and function of bombesin-like peptides and their
receptors</article-title><source>Int J Dev Biol</source><year>2005</year><volume>49</volume><fpage>293</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">15906244</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>O</given-names></name><name><surname>Shulkes</surname><given-names>A</given-names></name><name><surname>Baldwin</surname><given-names>GS</given-names></name></person-group><article-title>Gastrin-releasing peptide and cancer</article-title><source>Biochim Biophys Acta</source><year>2006</year><volume>1766</volume><fpage>23</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">16490321</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roesler</surname><given-names>R</given-names></name><name><surname>Henriques</surname><given-names>JAP</given-names></name><name><surname>Schwartsmann</surname><given-names>G</given-names></name></person-group><article-title>Gastrin-releasing peptide receptor as a molecular target for
psychiatric and neurological disorders</article-title><source>CNS Neurol Disord Drug Targets</source><year>2006</year><volume>5</volume><fpage>197</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">16611092</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moody</surname><given-names>TW</given-names></name><name><surname>Pert</surname><given-names>CB</given-names></name><name><surname>Rivier</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>MR</given-names></name></person-group><article-title>Bombesin: specific binding to rat brain membranes</article-title><source>Proc Natl Acad Sci USA</source><year>1978</year><volume>75</volume><fpage>5372</fpage><lpage>5376</lpage><pub-id pub-id-type="pmid">281686</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Battey</surname><given-names>J</given-names></name><name><surname>Wada</surname><given-names>E</given-names></name><name><surname>Corjay</surname><given-names>M</given-names></name></person-group><article-title>Molecular genetic analysis of two distinct receptors for
mammalian bombesin-like peptides</article-title><source>J Natl Cancer Inst Monogr</source><year>1992</year><volume>13</volume><fpage>141</fpage><lpage>144</lpage></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Battey</surname><given-names>JF</given-names></name><name><surname>Way</surname><given-names>JM</given-names></name><name><surname>Corjay</surname><given-names>MH</given-names></name></person-group><article-title>Molecular cloning of the bombesin/gastrin-releasing peptide
receptor from Swiss 3T3 cells</article-title><source>Proc Natl Acad Sci USA</source><year>1991</year><volume>88</volume><fpage>395</fpage><lpage>399</lpage><pub-id pub-id-type="pmid">1671171</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spindel</surname><given-names>ER</given-names></name><name><surname>Giladi</surname><given-names>E</given-names></name><name><surname>Brehm</surname><given-names>P</given-names></name><name><surname>Goodman</surname><given-names>RH</given-names></name><name><surname>Segerson</surname><given-names>TP</given-names></name></person-group><article-title>Cloning and functional characterization of a complementary DNA
encoding the murine fibroblast bombesin/gastrin-releasing peptide
receptor</article-title><source>Mol Endocrinol</source><year>1990</year><volume>4</volume><fpage>1956</fpage><lpage>1963</lpage><pub-id pub-id-type="pmid">1707129</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>SS</given-names></name><name><surname>Moody</surname><given-names>TW</given-names></name></person-group><article-title>Receptors for GRP/bombesin-like peptides in the rat
forebrain</article-title><source>Peptides</source><year>1985</year><volume>6</volume><fpage>111</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">2995940</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>SS</given-names></name><name><surname>Moody</surname><given-names>TW</given-names></name><name><surname>O'Donohue</surname><given-names>TL</given-names></name><name><surname>Zarbin</surname><given-names>MA</given-names></name><name><surname>Kuhar</surname><given-names>MJ</given-names></name></person-group><article-title>Autoradiographic visualization of rat brain binding sites for
bombesin-like peptides</article-title><source>Eur J Pharmacol</source><year>1983</year><volume>87</volume><fpage>163</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">6301851</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamichi</surname><given-names>S</given-names></name><name><surname>Wada</surname><given-names>E</given-names></name><name><surname>Aoki</surname><given-names>S</given-names></name><name><surname>Sekiguchi</surname><given-names>M</given-names></name><name><surname>Kimura</surname><given-names>I</given-names></name><name><surname>Wada</surname><given-names>K</given-names></name></person-group><article-title>Immunohistochemical localization of gastrin-releasing peptide
receptor in the mouse brain</article-title><source>Brain Res</source><year>2005</year><volume>1032</volume><fpage>162</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">15680955</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hellmich</surname><given-names>MR</given-names></name><name><surname>Ives</surname><given-names>KL</given-names></name><name><surname>Udupi</surname><given-names>V</given-names></name></person-group><article-title>Multiple protein kinase pathways are involved in
gastrin-releasing peptide receptor-regulated secretion</article-title><source>J Biol Chem</source><year>1999</year><volume>274</volume><fpage>23901</fpage><lpage>23909</lpage><pub-id pub-id-type="pmid">10446156</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Evers</surname><given-names>BM</given-names></name><name><surname>Litvak</surname><given-names>DA</given-names></name><name><surname>Hellmich</surname><given-names>MR</given-names></name><name><surname>Townsend</surname><given-names>CM Jr</given-names></name></person-group><article-title>Signaling mechanisms regulating bombesin-mediated AP-1 gene
induction in the human gastric cancer SIIA</article-title><source>Am J Physiol Cell Physiol</source><year>2000</year><volume>279</volume><fpage>C326</fpage><lpage>C334</lpage><pub-id pub-id-type="pmid">10912998</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>D</given-names></name><name><surname>Qu</surname><given-names>X</given-names></name><name><surname>Weber</surname><given-names>HC</given-names></name></person-group><article-title>Activation of extracellular signal-regulated kinase mediates
bombesin-induced mitogenic responses in prostate cancer
cells</article-title><source>Cell Signal</source><year>2003</year><volume>15</volume><fpage>945</fpage><lpage>953</lpage><pub-id pub-id-type="pmid">12873708</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Dixon</surname><given-names>AK</given-names></name><name><surname>Gonzalez</surname><given-names>I</given-names></name></person-group><article-title>Bombesin-like peptides depolarize rat hippocampal interneurones
through interaction with subtype 2 bombesin receptors</article-title><source>J Physiol</source><year>1999</year><volume>518</volume><fpage>791</fpage><lpage>802</lpage><pub-id pub-id-type="pmid">10420015</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roesler</surname><given-names>R</given-names></name><name><surname>Luft</surname><given-names>T</given-names></name><name><surname>Oliveira</surname><given-names>SH</given-names></name></person-group><article-title>Molecular mechanisms mediating gastrin-releasing peptide receptor
modulation of memory consolidation in the hippocampus</article-title><source>Neuropharmacology</source><year>2006</year><volume>51</volume><fpage>350</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">16735043</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roesler</surname><given-names>R</given-names></name><name><surname>Henriques</surname><given-names>JA</given-names></name><name><surname>Schwartsmann</surname><given-names>G</given-names></name></person-group><article-title>Neuropeptides and anxiety disorders: bombesin receptors as novel
therapeutic targets</article-title><source>Trends Pharmacol Sci</source><year>2004</year><volume>25</volume><fpage>241</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">15120487</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leissring</surname><given-names>MA</given-names></name><name><surname>Akbari</surname><given-names>Y</given-names></name><name><surname>Fanger</surname><given-names>CM</given-names></name><name><surname>Cahalan</surname><given-names>MD</given-names></name><name><surname>Mattson</surname><given-names>MP</given-names></name><name><surname>LaFerla</surname><given-names>FM</given-names></name></person-group><article-title>Capacitative calcium entry deficits and elevated luminal calcium
content in mutant presenilin-1 knockin mice</article-title><source>J Cell Biol</source><year>2000</year><volume>149</volume><fpage>793</fpage><lpage>798</lpage><pub-id pub-id-type="pmid">10811821</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Fu</surname><given-names>W</given-names></name><name><surname>Sopher</surname><given-names>BL</given-names></name></person-group><article-title>Increased vulnerability of hippocampal neurons to excitotoxic
necrosis in presenilin-1 mutant knock-in mice</article-title><source>Nat Med</source><year>1999</year><volume>5</volume><fpage>101</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">9883847</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>GE</given-names></name><name><surname>Huang</surname><given-names>HM</given-names></name></person-group><article-title>Oxidative stress in Alzheimer's disease</article-title><source>Neurobiol Aging</source><year>2005</year><volume>26</volume><fpage>575</fpage><lpage>578</lpage><pub-id pub-id-type="pmid">15708429</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>GE</given-names></name><name><surname>Vestling</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name></person-group><article-title>Abnormalities in Alzheimer's disease fibroblasts bearing the
APP670/671 mutation</article-title><source>Neurobiol Aging</source><year>1997</year><volume>18</volume><fpage>573</fpage><lpage>580</lpage><pub-id pub-id-type="pmid">9461055</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>GE</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Toral-Barza</surname><given-names>L</given-names></name><name><surname>Szolosi</surname><given-names>S</given-names></name><name><surname>Tofel-Grehl</surname><given-names>B</given-names></name></person-group><article-title>Calcium stores in cultured fibroblasts and their changes with
Alzheimer's disease</article-title><source>Biochim Biophys Acta</source><year>1996</year><volume>1316</volume><fpage>71</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">8672553</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>HM</given-names></name><name><surname>Chen</surname><given-names>HL</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Gibson</surname><given-names>GE</given-names></name></person-group><article-title>Modification of endoplasmic reticulum Ca2+ stores by select
oxidants produces changes reminiscent of those in cells from patients with
Alzheimer disease</article-title><source>Free Radic Biol Med</source><year>2005</year><volume>39</volume><fpage>979</fpage><lpage>989</lpage><pub-id pub-id-type="pmid">16198225</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>E</given-names></name><name><surname>Oka</surname><given-names>K</given-names></name><name><surname>Etcheberrigaray</surname><given-names>R</given-names></name></person-group><article-title>Internal Ca2+ mobilization is altered in fibroblasts from
patients with Alzheimer disease</article-title><source>Proc Natl Acad Sci USA</source><year>1994</year><volume>91</volume><fpage>534</fpage><lpage>538</lpage><pub-id pub-id-type="pmid">8290560</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>HM</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Ou</surname><given-names>HC</given-names></name><name><surname>Chen</surname><given-names>HL</given-names></name></person-group><article-title>Gibson GE alpha-keto-beta-methyl-n-valeric acid diminishes
reactive oxygen species and alters endoplasmic reticulum Ca(2+)
stores</article-title><source>Free Radic Biol Med</source><year>2004</year><volume>37</volume><fpage>1779</fpage><lpage>1789</lpage><pub-id pub-id-type="pmid">15528037</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flood</surname><given-names>JF</given-names></name><name><surname>Morley</surname><given-names>JE</given-names></name></person-group><article-title>Effects of bombesin and gastrin-releasing peptide on memory
processing</article-title><source>Brain Res</source><year>1988</year><volume>460</volume><fpage>314</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">3224263</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rashidy-Pour</surname><given-names>A</given-names></name><name><surname>Razvani</surname><given-names>ME</given-names></name></person-group><article-title>Unilateral reversible inactivations of the nucleus tractus
solitarius and amygdala attenuate the effects of bombesin on memory
storage</article-title><source>Brain Res</source><year>1998</year><volume>814</volume><fpage>127</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">9838077</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martins</surname><given-names>MR</given-names></name><name><surname>Reinke</surname><given-names>A</given-names></name><name><surname>Valvassori</surname><given-names>SS</given-names></name></person-group><article-title>Non-associative learning and anxiety in rats treated with a
single systemic administration of the gastrin-releasing peptide receptor
antagonist RC-3095</article-title><source>Peptides</source><year>2005</year><volume>26</volume><fpage>2525</fpage><lpage>2529</lpage><pub-id pub-id-type="pmid">16023260</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Presti-Torres</surname><given-names>J</given-names></name><name><surname>de Lima</surname><given-names>MN</given-names></name><name><surname>Scalco</surname><given-names>FS</given-names></name></person-group><article-title>Impairments of social behavior and memory after neonatal
gastrin-releasing peptide receptor blockade in rats: Implications for an
animal model of neurodevelopmental disorders</article-title><source>Neuropharmacology</source><year>2007</year><volume>52</volume><fpage>724</fpage><lpage>732</lpage><pub-id pub-id-type="pmid">17097693</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roesler</surname><given-names>R</given-names></name><name><surname>Kopschina</surname><given-names>MI</given-names></name><name><surname>Rosa</surname><given-names>RM</given-names></name><name><surname>Henriques</surname><given-names>JA</given-names></name><name><surname>Souza</surname><given-names>DO</given-names></name><name><surname>Schwartsmann</surname><given-names>G</given-names></name></person-group><article-title>RC-3095, a bombesin/gastrin-releasing peptide receptor
antagonist, impairs aversive but not recognition memory in
rats</article-title><source>Eur J Pharmacol</source><year>2004</year><volume>486</volume><fpage>35</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">14751406</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roesler</surname><given-names>R</given-names></name><name><surname>Lessa</surname><given-names>D</given-names></name><name><surname>Venturella</surname><given-names>R</given-names></name></person-group><article-title>Bombesin/gastrin-releasing peptide receptors in the basolateral
amygdala regulate memory consolidation</article-title><source>Eur J Neurosci</source><year>2004</year><volume>19</volume><fpage>1041</fpage><lpage>1045</lpage><pub-id pub-id-type="pmid">15009151</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santo-Yamada</surname><given-names>Y</given-names></name><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Wada</surname><given-names>E</given-names></name><name><surname>Goto</surname><given-names>Y</given-names></name><name><surname>Wada</surname><given-names>K</given-names></name></person-group><article-title>Blockade of bombesin-like peptide receptors impairs inhibitory
avoidance learning in mice</article-title><source>Neurosci Lett</source><year>2003</year><volume>340</volume><fpage>65</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">12648760</pub-id></element-citation></ref><ref id="r33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dantas</surname><given-names>AS</given-names></name><name><surname>Luft</surname><given-names>T</given-names></name><name><surname>Henriques</surname><given-names>JA</given-names></name><name><surname>Schwartsmann</surname><given-names>G</given-names></name><name><surname>Roesler</surname><given-names>R</given-names></name></person-group><article-title>Opposite effects of low and high doses of the gastrin-releasing
peptide receptor antagonist RC-3095 on memory consolidation in the
hippocampus: possible involvement of the GABAergic system</article-title><source>Peptides</source><year>2006</year><volume>27</volume><fpage>2307</fpage><lpage>2312</lpage><pub-id pub-id-type="pmid">16650508</pub-id></element-citation></ref><ref id="r34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luft</surname><given-names>T</given-names></name><name><surname>Flores</surname><given-names>DG</given-names></name><name><surname>Vianna</surname><given-names>MR</given-names></name><name><surname>Schwartsmann</surname><given-names>G</given-names></name><name><surname>Roesler</surname><given-names>R</given-names></name><name><surname>Izquierdo</surname><given-names>I</given-names></name></person-group><article-title>A role for hippocampal gastrin-releasing peptide receptors in
extinction of aversive memory</article-title><source>Neuroreport</source><year>2006</year><volume>17</volume><fpage>935</fpage><lpage>939</lpage><pub-id pub-id-type="pmid">16738491</pub-id></element-citation></ref><ref id="r35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mountney</surname><given-names>C</given-names></name><name><surname>Sillberg</surname><given-names>V</given-names></name><name><surname>Kent</surname><given-names>P</given-names></name><name><surname>Anisman</surname><given-names>H</given-names></name><name><surname>Merali</surname><given-names>Z</given-names></name></person-group><article-title>The role of gastrin-releasing peptide on conditioned fear:
differential cortical and amygdaloid responses in the rat</article-title><source>Psychopharmacology</source><year>2006</year><volume>189</volume><fpage>287</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">17033843</pub-id></element-citation></ref><ref id="r36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roesler</surname><given-names>R</given-names></name><name><surname>Meller</surname><given-names>CA</given-names></name><name><surname>Kopschina</surname><given-names>MI</given-names></name><name><surname>Souza</surname><given-names>DO</given-names></name><name><surname>Henriques</surname><given-names>JA</given-names></name><name><surname>Schwartsmann</surname><given-names>G</given-names></name></person-group><article-title>Intrahippocampal infusion of the bombesin/gastrin-releasing
peptide antagonist RC-3095 impairs inhibitory avoidance
retention</article-title><source>Peptides</source><year>2003</year><volume>24</volume><fpage>1069</fpage><lpage>1074</lpage><pub-id pub-id-type="pmid">14499286</pub-id></element-citation></ref><ref id="r37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venturella</surname><given-names>R</given-names></name><name><surname>Lessa</surname><given-names>D</given-names></name><name><surname>Luft</surname><given-names>T</given-names></name><name><surname>Roozendaal</surname><given-names>B</given-names></name><name><surname>Schwartsmann</surname><given-names>G</given-names></name><name><surname>Roesler</surname><given-names>R</given-names></name></person-group><article-title>Dexamethasone reverses the memory impairment induced by
antagonism of hippocampal gastrin-releasing peptide
receptors</article-title><source>Peptides</source><year>2005</year><volume>26</volume><fpage>821</fpage><lpage>825</lpage><pub-id pub-id-type="pmid">15808912</pub-id></element-citation></ref><ref id="r38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>CL</given-names></name><name><surname>McGaugh</surname><given-names>JL</given-names></name></person-group><article-title>Enhancement of memory processing in an inhibitory avoidance and
radial maze task by post-training infusion of bombesin into the nucleus
tractus solitarius</article-title><source>Brain Res</source><year>1994</year><volume>654</volume><fpage>251</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">7987675</pub-id></element-citation></ref><ref id="r39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shumyatsky</surname><given-names>GP</given-names></name><name><surname>Tsvetkov</surname><given-names>E</given-names></name><name><surname>Malleret</surname><given-names>G</given-names></name></person-group><article-title>Identification of a signaling network in lateral nucleus of
amygdala important for inhibiting memory specifically related to learned
fear</article-title><source>Cell</source><year>2002</year><volume>111</volume><fpage>905</fpage><lpage>918</lpage><pub-id pub-id-type="pmid">12526815</pub-id></element-citation></ref><ref id="r40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santo-Yamada</surname><given-names>Y</given-names></name><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Wada</surname><given-names>K</given-names></name></person-group><article-title>Posttraining administration of gastrin-releasing peptide improves
memory loss in scopolamine- and hypoxia-induced amnesic mice</article-title><source>Physiol Behav</source><year>2001</year><volume>74</volume><fpage>139</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">11564462</pub-id></element-citation></ref><ref id="r41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dal-Pizzol</surname><given-names>F</given-names></name><name><surname>Di Leone</surname><given-names>LP</given-names></name><name><surname>Ritter</surname><given-names>C</given-names></name></person-group><article-title>Gastrin-releasing peptide receptor antagonist effects on an
animal model of sepsis</article-title><source>Am J Respir Crit Care Med</source><year>2006</year><volume>173</volume><fpage>84</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">16192447</pub-id></element-citation></ref><ref id="r42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutzwiller</surname><given-names>JP</given-names></name><name><surname>Drewe</surname><given-names>J</given-names></name><name><surname>Hildebrand</surname><given-names>P</given-names></name><name><surname>Rossi</surname><given-names>L</given-names></name><name><surname>Lauper</surname><given-names>JZ</given-names></name><name><surname>Beglinger</surname><given-names>C</given-names></name></person-group><article-title>Effect of intravenous human gastrin-releasing peptide on food
intake in humans</article-title><source>Gastroenterology</source><year>1994</year><volume>106</volume><fpage>1168</fpage><lpage>1173</lpage><pub-id pub-id-type="pmid">8174879</pub-id></element-citation></ref><ref id="r43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartsmann</surname><given-names>G</given-names></name><name><surname>DiLeone</surname><given-names>LP</given-names></name><name><surname>Horowitz</surname><given-names>M</given-names></name></person-group><article-title>A phase I trial of the bombesin/gastrin-releasing peptide
(BB/GRP) antagonist RC3095 in patients with advanced solid
malignancies</article-title><source>Invest New Drugs</source><year>2006</year><volume>24</volume><fpage>403</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">16505950</pub-id></element-citation></ref></ref-list></back></article>